OCUL
Ocular Therapeutix·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 2
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Gap Up
Significant Net Income Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About OCUL
Ocular Therapeutix, Inc.
A biopharmaceutical company focused on innovative therapies for diseases and conditions of the eye
15 Crosby Drive, Bedford, MA 01730
--
Ocular Therapeutix, Inc., was established in Delaware on September 12, 2006. The company is a biopharmaceutical company dedicated to improving people's vision and quality of life by developing and commercializing innovative therapies for eye diseases and conditions, with a special focus on retinal diseases. The company's hydrogel-based bioabsorbable product candidate is designed to provide sustained release of therapeutic drugs to the eye. The Company's lead product candidates are drug-eluting punctal plug OTX-DP and punctal OTX-TP inserted into a natural opening called the punctum located on the inner part of the eyelid near the nose. The Company's canalicular suppository product candidate combines the Company's hydrogel technology with the U.S. Food and Drug Administration, or FDA-approved therapeutic drug for the purpose of providing continuous dosing to the eye.
Earnings Call
Q2/2025
Estimate EPS-0.35
Actual EPS-0.39
Estimate Revenue13.12M
Actual Revenue13.46M
Ocular Therapeutix Q2 2025: Unpacking Key Contradictions in SOL-R Trial Criteria and FDA Relations
Aug 05,2025 01:43
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
OCUL has released its 2025 Q3 earnings. EPS was reported at -0.38, versus the expected -0.35, missing expectations. The chart below visualizes how OCUL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OCUL has released its 2025 Q3 earnings report, with revenue of 14.54M, reflecting a YoY change of -5.71%, and net profit of -69.42M, showing a YoY change of -90.22%. The Sankey diagram below clearly presents OCUL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
